CD36 Receptor Enables Cellular Uptake of Large Cancer-Fighting PROTAC Drugs
Scientists discover how cells absorb large therapeutic molecules that shouldn't cross membranes, opening new drug design possibilities.
Summary
Researchers solved a major puzzle in drug delivery by discovering that CD36, a membrane receptor, acts as a cellular gateway for large therapeutic molecules called PROTACs. These protein-degrading drugs are typically too big to enter cells through normal pathways, yet they work effectively in patients. The team found CD36 binds to and transports PROTACs and other large drugs into cells via endocytosis. They then developed a chemical modification strategy that enhances PROTAC binding to CD36, improving both drug uptake and solubility simultaneously.
Detailed Summary
A breakthrough study published in Cell reveals how large therapeutic molecules overcome a fundamental barrier to enter cells, potentially revolutionizing drug design for cancer and other diseases. The research focused on PROTACs (proteolysis-targeting chimeras), innovative drugs that degrade disease-causing proteins but are typically too large (>800 Da) to cross cell membranes through passive diffusion.
Using biotinylated chemical probes and genetic techniques, researchers identified CD36, a membrane receptor protein, as the key transporter enabling cellular uptake of PROTACs. They demonstrated that CD36 binds to diverse PROTACs including clinical candidate ARV-110, as well as other large drugs like rapamycin and doxorubicin, facilitating their entry through the EEA1/Rab5 endosomal pathway.
The team tested this mechanism across multiple cell lines and animal models, confirming CD36's role in drug efficacy. Cells lacking CD36 showed dramatically reduced PROTAC uptake and therapeutic effect, while CD36 overexpression enhanced drug sensitivity.
Most importantly, researchers developed a novel "chemical endocytic medicinal chemistry" approach, modifying PROTAC structures to improve CD36 binding. This strategy simultaneously enhanced drug permeability, solubility, and stability without compromising therapeutic activity.
These findings explain how many "rule-breaking" drugs work despite violating traditional pharmaceutical guidelines for membrane permeability. The discovery opens new avenues for designing more effective therapeutics by optimizing CD36 interactions, potentially improving bioavailability and reducing dosing requirements for numerous medications.
Key Findings
- CD36 membrane receptor enables cellular uptake of large PROTACs and other drugs >800 Da
- CD36 knockout cells show dramatically reduced PROTAC efficacy and drug uptake
- Chemical modifications enhancing CD36 binding improve PROTAC permeability and solubility
- Discovery explains how rule-breaking drugs cross cell membranes despite large size
- New drug design strategy could improve bioavailability of diverse therapeutics
Methodology
Researchers used biotinylated chemical probes for target identification, genetic knockout/knockin approaches in multiple cell lines, and tested drug uptake both in vitro and in animal models. They employed structural modifications via prodrug approaches to enhance CD36 binding.
Study Limitations
Study primarily used cancer cell lines and may not apply to all tissue types. Long-term safety of enhanced CD36 targeting requires further investigation. Clinical translation of the chemical modification strategy needs validation in human trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.